Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in Adult Immune Thrombocytopenia (DART)
NCT04703621Phase 2Unknown
- Sponsor
- Ostfold Hospital Trust
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of daratumumab in immune thrombocytopenia (ITP) (3 arms), sponsored by Ostfold Hospital Trust. Primary endpoints: Evaluation of response after daratumumab treatment at 16 weeks and Safety of daratumumab at 24 weeks. Status: unknown.
02
Drugs
daratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT04703621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703621.